Aktis Oncology (AKTS) holders convert preferred and buy common
Rhea-AI Filing Summary
Vida Ventures II, LLC and Vida Ventures II-A, LLC, both 10% owners of Aktis Oncology, Inc., reported multiple transactions dated 01/12/2026. Series A and Series B Redeemable Convertible Preferred Stock automatically converted into Common Stock on a 3.8044-for-1 basis immediately before the closing of Aktis Oncology’s initial public offering, with no additional consideration paid.
Following these conversions and open-market purchases, Vida Ventures II, LLC indirectly held 5,671,825 shares of Common Stock after acquiring 4,859,370 shares through conversion and buying 812,455 shares at $18 per share. Vida Ventures II-A, LLC indirectly held 157,387 shares of Common Stock after receiving 134,842 shares through conversion and purchasing 22,545 shares at $18 per share.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series A Redeemable Convertible Preferred Stock | 14,838,250 | $0.00 | -- |
| Conversion | Series A Redeemable Convertible Preferred Stock | 411,750 | $0.00 | -- |
| Conversion | Series B Redeemable Convertible Preferred Stock | 3,648,750 | $0.00 | -- |
| Conversion | Series B Redeemable Convertible Preferred Stock | 101,250 | $0.00 | -- |
| Conversion | Common Stock | 4,859,370 | $0.00 | -- |
| Purchase | Common Stock | 812,455 | $18.00 | $14.62M |
| Conversion | Common Stock | 134,842 | $0.00 | -- |
| Purchase | Common Stock | 22,545 | $18.00 | $406K |
Footnotes (1)
- Represents shares of the Issuer's Common Stock received upon conversion of shares of the Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock on a 3.8044-for-1 basis without payment of additional consideration. These shares are held by Vida Ventures II, LLC ("VV II"). VV Manager II, LLC ("VVM II") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein. These shares are held by Vida Ventures II-A, LLC ("VV II-A"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein. The Series A Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration. The Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.
FAQ
What insider activity did Vida Ventures report in Aktis Oncology (AKTS)?
Vida Ventures II, LLC and Vida Ventures II-A, LLC reported automatic conversion of Aktis Oncology Series A and B Redeemable Convertible Preferred Stock into Common Stock and open-market purchases of additional Common Stock on 01/12/2026.
What was the conversion ratio for Aktis Oncology preferred stock in this Form 4?
The Series A and Series B Redeemable Convertible Preferred Stock automatically converted into Aktis Oncology Common Stock on a 3.8044-for-1 basis, without payment of additional consideration.